Literature DB >> 11952454

Use of remifentanil for awake fiberoptic intubation in a morbidly obese patient with severe inflammation of the neck.

W Puchner1, J Obwegeser, F K Pühringer.   

Abstract

Impending upper airway obstruction due to odontogenic facial and cervical spreading infection is a potential fatal situation that requires urgent treatment. In particular, securing the threatened airway is a priority and a precondition to the pressing need for surgery. The best approach to establish the difficult airway is awake fiberoptic intubation or scheduled tracheotomy under local anesthesia. We report a critical case of severe swelling of the neck in a morbidly obese patient with no alternative to awake fiberoptic intubation. The primary goals of optimal safety for the patient and appropriate intubating conditions for the anesthesiologist made us to consider a new method of patient medication.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11952454     DOI: 10.1034/j.1399-6576.2002.460426.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  4 in total

1.  Successful intubation of a difficult airway due to a large obstructive vocal cord polyp augmented by the delivery of a transtracheal injection of local anaesthetic.

Authors:  Jayan George; Jishar Abdul Kader; Sivasundari Arumugam; Anthony Murphy
Journal:  BMJ Case Rep       Date:  2015-12-01

Review 2.  Remifentanil update: clinical science and utility.

Authors:  Richard Beers; Enrico Camporesi
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 3.  A growing problem: implications of obesity on the provision of trauma care.

Authors:  Ahmed Twaij; Mikael H Sodergren; Philip H Pucher; Nicola Batrick; Sanjay Purkayastha
Journal:  Obes Surg       Date:  2013-12       Impact factor: 4.129

4.  Dexmedetomidine versus remifentanil sedation during awake fiberoptic nasotracheal intubation: a double-blinded randomized controlled trial.

Authors:  Rong Hu; J X Liu; Hong Jiang
Journal:  J Anesth       Date:  2012-10-17       Impact factor: 2.078

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.